Healthcare Industry News: Allergan
News Release - June 16, 2010
Bausch & Lomb Names Robert E. Grant as CEO and President of Its Surgical BusinessROCHESTER, NY, June 16--(HSMN NewsFeed) - Bausch & Lomb, the global eye health company, has named Robert E. Grant chief executive officer and president of its global Surgical business, effective August 1.
"Robert is an exceptional leader and innovator in the medical products industry, with global operating expertise extending across devices and pharmaceuticals," said Brent Saunders, chief executive officer, Bausch & Lomb. "His recruitment is another successful step in the actions we are implementing to transform Bausch & Lomb into a high-performance global competitor."
Continued Mr. Saunders, "Robert is the right person at the right time for B&L. He brings a track record of rapid value creation, powerful leadership and a relentless focus on the customer that can take our Surgical business to a new level of performance -- while also helping us to build strength and execution excellence across the company."
"I am very excited to join Bausch & Lomb. I am confident that the company will create tremendous value, push product development to new heights, and play a leading role in the future of the global ophthalmic industry," commented Mr. Grant. "With a state-of-the-art product portfolio and a keen focus on the customer, we will lead innovation and growth in this dynamic market segment."
In 2006, Mr. Grant began his tenure as Allergan's corporate vice president and president, Allergan Medical, where he led the $3.4 billion Allergan-Inamed post-acquisition integration. His leadership at Allergan Medical was instrumental in creating the multi-billion dollar medical rejuvenation industry through a portfolio of products such as BOTOX® Cosmetic, JUVEDERM® injectable gel, NATRELLE® breast implants and the LAP-BAND® Adjustable Gastric Banding System.
Prior, Mr. Grant served as acting chairman, president and CEO of BIOLASE Technology, Inc., the global cosmetic dentistry company, where he led a highly successful turnaround, returning the company to profitability and revenue growth. He joined BIOLASE in 2003 as chief operating officer, and also served the organization as chief financial officer.
From 1997 to 2003, Mr. Grant held management positions with Lumenis, Inc. (formerly Coherent Medical Group), including executive vice president of its Ophthalmic Business Unit, executive vice president of its Surgical Business Unit, vice president of business development and managing director of European Operations. He has also held expatriate management positions with Sulzer Medica AG and Telectronics Pty Ltd. Mr. Grant has lived and worked in nine countries and is fluent in English, Japanese, French, Korean and German.
Mr. Grant earned his M.B.A. from the Thunderbird School of Global Management and has a bachelor's degree from Brigham Young University. He will be based in Aliso Viejo, Calif.
J. Andy Corley, the president of Bausch & Lomb's Surgical business since 2008, will transition into a role as senior advisor to Brent Saunders and the B&L senior leadership team. "Andy has played a decisive role in building and positioning our Surgical business for future success, and he has also made very important contributions to the evolution of B&L as a whole," said Mr. Saunders. "We thank him for what he has achieved. We will value Andy's continued advice and counsel as we continue the positive transformation of our company."
About Bausch & Lomb
Bausch & Lomb is dedicated to bringing visionary ideas to eye health. Its core businesses include contact lenses and lens care products, ophthalmic surgical devices and instruments, and ophthalmic pharmaceuticals. The Bausch & Lomb name is one of the best-known and most respected healthcare brands in the world. Founded in 1853, the company is headquartered in Rochester, N.Y., and employs more than 10,000 people worldwide. Its products are available in more than 100 countries. More information is available at www.bausch.com.
Source: Bausch & Lomb
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.